Acticam

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
24-03-2021

Ingredient activ:

meloxicam

Disponibil de la:

Ecuphar

Codul ATC:

QM01AC06

INN (nume internaţional):

meloxicam

Grupul Terapeutică:

Dogs; Cats

Zonă Terapeutică:

Anti inflammatory and antirheumatic products

Indicații terapeutice:

Oral suspension:Dogs:Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.Solution for injection:Dogs:Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.Reduction of postoperative pain and inflammation following orthopaedic and soft-tissue surgery.Cats:Reduction of postoperative pain after ovariohysterectomy and minor soft-tissue surgery.

Rezumat produs:

Revision: 9

Statutul autorizaţiei:

Withdrawn

Data de autorizare:

2008-12-09

Prospect

                                Medicinal product no longer authorised
14
B. PACKAGE LEAFLET
Medicinal product no longer authorised
15
PACKAGE LEAFLET:
ACTICAM 5 MG/ML SOLUTION FOR INJECTION FOR DOGS AND CATS
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Ecuphar NV
Legeweg 157-i
B-8020 Oostkamp
Belgium
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Acticam 5 mg/ml solution for injection for dogs and cats.
Meloxicam.
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Meloxicam 5 mg/ml.
Ethanol anhydrous 150 mg/ml.
4.
INDICATION(S)
Dogs:
Alleviation of inflammation and pain in both acute and chronic
musculo-skeletal disorders. Reduction
of post-operative pain and inflammation following orthopaedic and soft
tissue surgery.
Cats:
Reduction of post-operative pain after ovariohysterectomy and minor
soft tissue surgery.
5.
CONTRAINDICATIONS
Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastrointestinal disorders such
as irritation and haemorrhage,
impaired hepatic, cardiac or renal function and haemorrhagic
disorders.
Do not use in cases of hypersensitivity to the active substance or to
any of the excipients.
Do not use in animals less than 6 weeks of age nor in cats of less
than 2 kg.
6.
ADVERSE REACTIONS
Typical adverse reactions of NSAIDs such as loss of appetite,
vomiting, diarrhoea, faecal occult blood,
lethargy and renal failure have occasionally been reported. In very
rare cases elevated liver enzymes
have been reported. In dogs, in very rare cases, haemorrhagic
diarrhoea, haematemesis and
gastrointestinal ulceration have been reported. In dogs, these side
effects occur generally within the
first treatment week and are in most cases transient and disappear
following termination of the
treatment but in very rare cases may be serious or fatal. In very rare
cases anaphylactoid reactions may
occur and should be treated symptomatically.
Medicinal product no longer authorised
16
If adverse reactions occur
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                Medicinal product no longer authorised
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Acticam 5 mg/ml solution for injection for dogs and cats.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE:
Meloxicam 5 mg.
EXCIPIENTS:
Ethanol, anhydrous 150 mg.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
A clear yellow solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs and cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Dogs:
Alleviation of inflammation and pain in both acute and chronic
musculo-skeletal disorders. Reduction
of post-operative pain and inflammation following orthopaedic and soft
tissue surgery.
Cats:
Reduction of post-operative pain after ovariohysterectomy and minor
soft tissue surgery.
4.3
CONTRAINDICATIONS
Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastrointestinal disorders such
as irritation and haemorrhage,
impaired hepatic, cardiac or renal function and haemorrhagic
disorders.
Do not use in cases of hypersensitivity to the active substance or to
any of the excipients.
Do not use in animals less than 6 weeks of age nor in cats of less
than 2 kg.
Do not use an oral follow-up therapy using meloxicam or other NSAIDs
in cats, as no safe dosage for
repeated oral administration has been established.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
For post-operative pain relief in cats, safety has only been
documented after thiopental/halothane
anaesthesia.
Medicinal product no longer authorised
3
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
If side effects occur, treatment should be discontinued.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as
there is a potential risk of
increased renal toxicity.
Special precautions to be taken by the person administering the
veterinary medicinal product to
animals
Accidental self-injection may give rise to pain.
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului bulgară 24-03-2021
Raport public de evaluare Raport public de evaluare bulgară 24-03-2021
Prospect Prospect spaniolă 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului spaniolă 24-03-2021
Raport public de evaluare Raport public de evaluare spaniolă 24-03-2021
Prospect Prospect cehă 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului cehă 24-03-2021
Raport public de evaluare Raport public de evaluare cehă 24-03-2021
Prospect Prospect daneză 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului daneză 24-03-2021
Raport public de evaluare Raport public de evaluare daneză 24-03-2021
Prospect Prospect germană 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului germană 24-03-2021
Raport public de evaluare Raport public de evaluare germană 24-03-2021
Prospect Prospect estoniană 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului estoniană 24-03-2021
Raport public de evaluare Raport public de evaluare estoniană 24-03-2021
Prospect Prospect greacă 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului greacă 24-03-2021
Raport public de evaluare Raport public de evaluare greacă 24-03-2021
Prospect Prospect franceză 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului franceză 24-03-2021
Raport public de evaluare Raport public de evaluare franceză 24-03-2021
Prospect Prospect italiană 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului italiană 24-03-2021
Raport public de evaluare Raport public de evaluare italiană 24-03-2021
Prospect Prospect letonă 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului letonă 24-03-2021
Raport public de evaluare Raport public de evaluare letonă 24-03-2021
Prospect Prospect lituaniană 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului lituaniană 24-03-2021
Raport public de evaluare Raport public de evaluare lituaniană 24-03-2021
Prospect Prospect maghiară 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului maghiară 24-03-2021
Raport public de evaluare Raport public de evaluare maghiară 24-03-2021
Prospect Prospect malteză 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului malteză 24-03-2021
Raport public de evaluare Raport public de evaluare malteză 24-03-2021
Prospect Prospect olandeză 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului olandeză 24-03-2021
Raport public de evaluare Raport public de evaluare olandeză 24-03-2021
Prospect Prospect poloneză 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului poloneză 24-03-2021
Raport public de evaluare Raport public de evaluare poloneză 24-03-2021
Prospect Prospect portugheză 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului portugheză 24-03-2021
Raport public de evaluare Raport public de evaluare portugheză 24-03-2021
Prospect Prospect română 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului română 24-03-2021
Raport public de evaluare Raport public de evaluare română 24-03-2021
Prospect Prospect slovacă 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului slovacă 24-03-2021
Raport public de evaluare Raport public de evaluare slovacă 24-03-2021
Prospect Prospect slovenă 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului slovenă 24-03-2021
Raport public de evaluare Raport public de evaluare slovenă 24-03-2021
Prospect Prospect finlandeză 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului finlandeză 24-03-2021
Raport public de evaluare Raport public de evaluare finlandeză 24-03-2021
Prospect Prospect suedeză 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului suedeză 24-03-2021
Raport public de evaluare Raport public de evaluare suedeză 24-03-2021
Prospect Prospect norvegiană 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului norvegiană 24-03-2021
Prospect Prospect islandeză 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului islandeză 24-03-2021
Prospect Prospect croată 24-03-2021
Caracteristicilor produsului Caracteristicilor produsului croată 24-03-2021

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor